• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·EVMN
Held by 2 Gurus
Share

Evommune, Inc. Stocks

$ 6.25Last Updated 09.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 226.83M

$ 6.25
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Steven Cohen

Portfolio Weight (%)

0.0%

Change

+0.02%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Steven CohenPoint72 Asset Management, L.P.0.0%+0.02%
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Latest news

09.11.2025 22:00

OpenAI isn't thinking about an exchange, "Tesla in the sky" raised $1 billion: the main thing about the IPO by Nov. 9

06.11.2025 14:58

Evommune IPO: shares in atopic dermatitis treatment developer become available

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 00:49

Trump announced an "energy truce" between Ukraine and Russia. What do analysts think?

11.10.2026 21:01

A Warning Sign for the AI Market: DeepSeek Seeks $12 Billion—Key Details on the IPO as of October 11

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026